Mark Löwenberg

8.4k total citations · 2 hit papers
166 papers, 4.9k citations indexed

About

Mark Löwenberg is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Mark Löwenberg has authored 166 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Genetics, 100 papers in Epidemiology and 53 papers in Surgery. Recurrent topics in Mark Löwenberg's work include Inflammatory Bowel Disease (124 papers), Microscopic Colitis (88 papers) and Eosinophilic Esophagitis (17 papers). Mark Löwenberg is often cited by papers focused on Inflammatory Bowel Disease (124 papers), Microscopic Colitis (88 papers) and Eosinophilic Esophagitis (17 papers). Mark Löwenberg collaborates with scholars based in Netherlands, Belgium and United States. Mark Löwenberg's co-authors include Geert D’Haens, Daniël W. Hommes, Gijs R. van den Brink, Cyriel Y. Ponsioen, Frank Buttgereit, Ron A. A. Mathôt, K Gecse, Johannan F. Brandse, Anne S. Strik and Jeroen M. Jansen and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mark Löwenberg

156 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis

2015 704 citations Mark Löwenberg, Gijs R. van den Brink et al. Gastroenterology profile →
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

2015 304 citations Johannan F. Brandse, Gijs R. van den Brink et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Löwenberg Netherlands	36	2.9k	2.2k	1.1k	1.0k	989	166	4.9k
Gábor Veres Hungary	40	2.9k 1.0×	1.8k 0.8×	1.6k 1.4×	875 0.8×	1.9k 1.9×	241	6.2k
Willem J.S. de Villiers United States	37	4.4k 1.5×	3.6k 1.7×	1.8k 1.6×	2.2k 2.1×	1.2k 1.2×	76	7.5k
Michael Fried Switzerland	41	2.0k 0.7×	1.3k 0.6×	1.3k 1.2×	613 0.6×	1.5k 1.5×	105	5.2k
Makoto Naganuma Japan	37	1.9k 0.7×	1.4k 0.6×	1.2k 1.1×	935 0.9×	1.1k 1.2×	233	4.8k
Stanley A. Cohen United States	37	2.6k 0.9×	1.6k 0.7×	1.4k 1.3×	690 0.7×	586 0.6×	91	4.5k
Vijay Yajnik United States	37	2.1k 0.7×	1.5k 0.7×	1.1k 1.0×	1.4k 1.3×	2.5k 2.5×	106	6.1k
David Q. Shih United States	38	2.1k 0.7×	1.2k 0.5×	1.9k 1.7×	1.0k 1.0×	1.5k 1.6×	122	5.1k
William A. Faubion United States	46	4.1k 1.4×	3.3k 1.5×	2.4k 2.1×	2.6k 2.5×	1.4k 1.4×	195	8.9k
Joanna M. M. Howson United Kingdom	39	3.0k 1.0×	780 0.4×	1.4k 1.2×	1.7k 1.7×	1.2k 1.2×	68	5.6k
Taku Kobayashi Japan	36	2.6k 0.9×	1.6k 0.7×	996 0.9×	1.8k 1.8×	1.4k 1.5×	161	5.3k

Countries citing papers authored by Mark Löwenberg

Since Specialization

Citations

This map shows the geographic impact of Mark Löwenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Löwenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Löwenberg more than expected).

Fields of papers citing papers by Mark Löwenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Löwenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Löwenberg. The network helps show where Mark Löwenberg may publish in the future.

Co-authorship network of co-authors of Mark Löwenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Löwenberg. A scholar is included among the top collaborators of Mark Löwenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Löwenberg. Mark Löwenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boneh, Rotem Sigall, Eytan Wine, Tim G. J. de Meij, et al.. (2025). Tryptophan metabolites profile predict remission with dietary therapy in pediatric Crohn’s disease. Therapeutic Advances in Gastroenterology. 18. 1128505980–1128505980. 1 indexed citations

Krens, Stefanie D., et al.. (2025). Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies. British Journal of Clinical Pharmacology. 91(11). 3130–3140.

Baert, Filip, Peter Bossuyt, Mark Löwenberg, et al.. (2025). DOP049 Vedolizumab is more effective at inducing histo-endoscopic healing in early Crohn’s Disease compared to late CD, with comparable healing rates regardless of disease location: data from the LOVE-CD trial. Journal of Crohn s and Colitis. 19(Supplement_1). i177–i179.

Jairath, Vipul, Brian G. Feagan, Mark S. Silverberg, et al.. (2024). Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. 23(2). 321–330.e3. 1 indexed citations

Evertsz, Floor Bennebroek, Claudi Bockting, Annemarie Braamse, et al.. (2024). Implementation of ‘IBD-Specific Cognitive Behavioural Therapy’ for Patients with Inflammatory Bowel Diseases with Poor Mental Quality of Life, Anxiety and Depression. Journal of Clinical Psychology in Medical Settings. 31(2). 258–278. 5 indexed citations

Hens, Bart, Tamás Molnár, Filip Baert, et al.. (2024). P845 Vedolizumab induces endoscopic healing uniformly irrespective of disease location: post-hoc analysis of the LOVE-CD trial. Journal of Crohn s and Colitis. 18(Supplement_1). i1560–i1561. 3 indexed citations

Travis, Simon, Mark S. Silverberg, Silvio Danese, et al.. (2023). Vedolizumab for the Treatment of Chronic Pouchitis. New England Journal of Medicine. 388(13). 1191–1200. 58 indexed citations

Peyrin‐Biroulet, Laurent, Séverine Vermeire, Geert D’Haens, et al.. (2023). Clinical trial: Clinical and endoscopic outcomes with ustekinumab in patients with Crohn's disease: Results from the long‐term extension period of STARDUST. Alimentary Pharmacology & Therapeutics. 59(2). 175–185. 9 indexed citations

Roest, Manon van, Jan Verhoeff, Joep Grootjans, et al.. (2023). P110 activation protein is strongly expressed in intestinal fibrosis in inflammatory bowel disease patients. Journal of Crohn s and Colitis. 17(Supplement_1). i273–i276. 1 indexed citations

10.

Joustra, V, Andrew Y. F. Li Yim, Evgeni Levin, et al.. (2023). Peripheral Blood DNA Methylation Signatures and Response to Tofacitinib in Moderate-to-severe Ulcerative Colitis. Journal of Crohn s and Colitis. 18(8). 1179–1189. 5 indexed citations

11.

Verhoeff, Jan, Geert D’Haens, Joep Grootjans, et al.. (2023). Tu1255 FIBROBLAST ACTIVATION PROTEIN (FAP) IS STRONGLY EXPRESSED IN INTESTINAL FIBROSIS IN INFLAMMATORY BOWEL DISEASE PATIENTS. Gastroenterology. 164(6). S–1009.

12.

Jairath, Vipul, Brian G. Feagan, Mark S. Silverberg, et al.. (2023). Sa1151 MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CHRONIC POUCHITIS: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Gastroenterology. 164(6). S–303. 1 indexed citations

13.

Bots, Steven, F de Voogd, Menno D. de Jong, et al.. (2021). Point-of-care Intestinal Ultrasound in IBD Patients: Disease Management and Diagnostic Yield in a Real-world Cohort and Proposal of a Point-of-care Algorithm. Journal of Crohn s and Colitis. 16(4). 606–615. 34 indexed citations

14.

Voskuil, Michiel, Lieke M. Spekhorst, Kimberley W. J. van der Sloot, et al.. (2020). Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. Journal of Crohn s and Colitis. 15(6). 930–937. 10 indexed citations

15.

Joustra, V, Annie Yim, K Gecse, et al.. (2020). P823 DNA methylation profiles accurately predict vedolizumab response and remain stable during induction and maintenance treatment in Crohn’s disease. Journal of Crohn s and Colitis. 14(Supplement_1). S639–S640. 2 indexed citations

16.

Biemans, Vince, C. Janneke van der Woude, Gerard Dijkstra, et al.. (2020). Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment. Alimentary Pharmacology & Therapeutics. 52(1). 123–134. 76 indexed citations

17.

Bots, Steven, et al.. (2017). Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.. PubMed. 75(10). 432–442. 8 indexed citations

18.

Löwenberg, Mark, et al.. (2014). P470 High infliximab trough levels are associated with impaired quality of life in IBD patients in clinical and biochemical remission on maintenance IFX therapy. Journal of Crohn s and Colitis. 8. S262–S263. 2 indexed citations

19.

Gecse, K, Reena Khanna, Gijs R. van den Brink, et al.. (2013). Biosimilars in IBD: hope or expectation?. Gut. 62(6). 803–807. 34 indexed citations

20.

Löwenberg, Mark, Auke P. Verhaar, Bernt van den Blink, et al.. (2005). Specific Inhibition of c-Raf Activity by Semapimod Induces Clinical Remission in Severe Crohn’s Disease. The Journal of Immunology. 175(4). 2293–2300. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact